Short Interest in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Declines By 17.5%

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) saw a significant decline in short interest in the month of December. As of December 31st, there was short interest totalling 4,540,000 shares, a decline of 17.5% from the December 15th total of 5,500,000 shares. Based on an average daily volume of 1,310,000 shares, the days-to-cover ratio is presently 3.5 days.

Zentalis Pharmaceuticals Price Performance

ZNTL opened at $2.24 on Friday. The business has a fifty day moving average price of $3.20 and a 200 day moving average price of $3.39. Zentalis Pharmaceuticals has a 12 month low of $2.16 and a 12 month high of $18.07. The stock has a market capitalization of $159.62 million, a price-to-earnings ratio of -0.90 and a beta of 1.86.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.36. On average, research analysts anticipate that Zentalis Pharmaceuticals will post -2.48 earnings per share for the current year.

Institutional Investors Weigh In On Zentalis Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of ZNTL. GSA Capital Partners LLP increased its holdings in Zentalis Pharmaceuticals by 138.5% in the third quarter. GSA Capital Partners LLP now owns 608,585 shares of the company’s stock valued at $2,240,000 after buying an additional 353,384 shares during the last quarter. Decheng Capital LLC increased its holdings in shares of Zentalis Pharmaceuticals by 46.2% in the 2nd quarter. Decheng Capital LLC now owns 3,070,442 shares of the company’s stock valued at $12,558,000 after acquiring an additional 970,859 shares during the last quarter. XTX Topco Ltd increased its holdings in shares of Zentalis Pharmaceuticals by 1,581.9% in the 2nd quarter. XTX Topco Ltd now owns 178,465 shares of the company’s stock valued at $730,000 after acquiring an additional 167,854 shares during the last quarter. Verition Fund Management LLC raised its position in shares of Zentalis Pharmaceuticals by 172.1% during the 3rd quarter. Verition Fund Management LLC now owns 1,504,320 shares of the company’s stock worth $5,536,000 after acquiring an additional 951,500 shares in the last quarter. Finally, Barclays PLC lifted its stake in Zentalis Pharmaceuticals by 18.5% during the third quarter. Barclays PLC now owns 75,395 shares of the company’s stock worth $277,000 after purchasing an additional 11,748 shares during the last quarter.

Analyst Ratings Changes

Several research analysts have recently commented on ZNTL shares. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Guggenheim dropped their target price on Zentalis Pharmaceuticals from $12.00 to $8.00 and set a “buy” rating for the company in a research report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $10.00.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.